AGP Picks
View all

ChemExpress reports clean first FDA inspection at Ma'anshan site

Nov. 2, 2026
ChemExpress reports clean first FDA inspection at Ma'anshan site
By AI, Created 09:10 UTC, Nov 02, 2026, AGP -

ChemExpress said its Ma'anshan, China, site received an FDA Establishment Inspection Report after its first U.S. inspection in August 2026, with no Form FDA 483 observations. The result bolsters the company’s push to expand API and HPAPI CDMO services for regulated global markets.

Why it matters: - The FDA outcome gives ChemExpress a key quality signal for customers that rely on compliant API and HPAPI manufacturing. - A clean first inspection can support the company’s ability to serve regulated markets in the U.S. and elsewhere. - The result strengthens ChemExpress’ CDMO pitch as drug developers look for manufacturing partners that can move programs from development to commercial supply.

What happened: - ChemExpress said its wholly owned subsidiary, Anhui Haoyuan Pharmaceutical, received the FDA’s Establishment Inspection Report after an August 2026 inspection of the Taodian Avenue Division, commonly called the Ma'anshan site. - The inspection was the site’s first U.S. FDA inspection. - The FDA issued no Form FDA 483 observations. - The inspection was conducted under the FDA’s Fiscal Year 2026 work plan and Compliance Program CPGM 7356.002F for active pharmaceutical ingredient process inspections.

The details: - FDA investigators used a systems-based approach to evaluate six cGMP systems. - The systems covered quality, facilities and equipment, materials, production, packaging and labeling, and laboratory control. - The inspection also reviewed manufacturing operations for APIs and pharmaceutical intermediates intended for human drug products supplied to the U.S. market. - ChemExpress said the result reflects ongoing investment in quality management, manufacturing controls and cGMP-compliant operations. - The company said the Ma'anshan site supports API and highly potent API CDMO services. - The site’s capabilities include process scale-up, cGMP manufacturing and commercial supply. - ChemExpress said quality and compliance are built into process development, technology transfer, scale-up, quality control, cGMP manufacturing and commercial production.

Between the lines: - A first inspection without observations can help reduce regulatory friction for a manufacturing site trying to win or retain global business. - The outcome also suggests ChemExpress is using compliance as a commercial differentiator, not just a regulatory requirement. - The company is positioning the Ma'anshan site as part of a broader integrated network that can support programs from early development through commercialization.

What's next: - ChemExpress said it will keep strengthening quality systems and operational capabilities in line with international cGMP standards. - The company plans to use its R&D, process chemistry and manufacturing scale-up capabilities to support future API, HPAPI and related CDMO projects. - Dr. Yonggang Chen, SVP and CTO of ChemExpress, said the company will continue to provide reliable, compliant and high-quality CDMO services to global customers. - ChemExpress said it aims to expand end-to-end CRO and CDMO offerings for pharmaceutical and biotechnology partners as it grows its global service network.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Investor News Updates

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Investor News Updates

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.